Precision BioSciences (NASDAQ:DTIL) Trading Up 3.6% – Here’s Why

Precision BioSciences, Inc. (NASDAQ:DTIL)’s share price traded up 3.6% during trading on Thursday . The stock traded as high as $7.17 and last traded at $7.11. 77,368 shares changed hands during mid-day trading, a decline of 2% from the average session volume of 79,007 shares. The stock had previously closed at $6.86.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of Precision BioSciences in a research report on Thursday, August 22nd.

Precision BioSciences Stock Performance

The firm has a fifty day moving average price of $8.40 and a two-hundred day moving average price of $9.71. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22. The stock has a market capitalization of $55.91 million, a PE ratio of 121.52 and a beta of 1.71.

Institutional Trading of Precision BioSciences

An institutional investor recently bought a new position in Precision BioSciences stock. Janus Henderson Group PLC acquired a new stake in Precision BioSciences, Inc. (NASDAQ:DTIL) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 573,052 shares of the company’s stock, valued at approximately $7,739,000. Janus Henderson Group PLC owned 8.29% of Precision BioSciences at the end of the most recent reporting period. 37.99% of the stock is currently owned by institutional investors.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.